Bain Capital

About Us
About us Explore

Overview

Purpose and values

How we partner

Our global presence
Committed to lasting impact
Our purpose, in our words
Businesses
Private Equity
HOW WE CREATE VALUE
Transforming businesses through deep sector expertise and capabilities.
HOW WE INVEST
Global Private Equity>
Double Impact>
Insurance>
Growth & Venture
HOW WE CREATE VALUE
Accelerating seed-to-scale growth in partnership with visionary leaders.
HOW WE INVEST
Ventures>
Life Sciences>
Tech Opportunities>
Crypto>
Capital Solutions
HOW WE CREATE VALUE
Structuring bespoke solutions across asset types, industries, markets, and business life cycles.
HOW WE INVEST
Special Situations>
Partnership Strategies>
Credit & Capital Markets
HOW WE CREATE VALUE
Enabling growth through innovative fund strategies and investment solutions across the capital structure.
HOW WE INVEST
Credit>
Public Equity>
Real Assets
HOW WE CREATE VALUE
Building the next generation of real assets.
HOW WE INVEST
Real Estate>
Special Situations>
ESG & Impact
ESG & Impact Explore

Active governance & stewardship

Sustainable growth & reducing climate impact

Fair employment, engagement & well-being

Diversity, equity & inclusion

Community engagement
2024 ESG Report JULY 19, 2023
Stewardship & sustainability
People
Careers
CAREERS Explore

Opportunity

Growth

Join us
Fulfill your potential
Our people are the heart of our advantage
News
NEWS View All

Press releases

In the news
PRESS RELEASES Special Situations Nov 18, 2024

Bain Capital Closes Global Special Situations Fund

TAVR developer JenaValve nets $50M from Bain Capital Life Sciences

TAVR developer JenaValve nets $50M from Bain Capital Life Sciences

Share this page

Bain Capital

Local Sites

OUR BUSINESSES

Private Equity

HOW WE CREATE VALUE

HOW WE INVEST

Growth & Venture

HOW WE CREATE VALUE

HOW WE INVEST

Capital Solutions

HOW WE CREATE VALUE

HOW WE INVEST

Credit & Capital Markets

HOW WE CREATE VALUE

HOW WE INVEST

Real Assets

HOW WE CREATE VALUE

HOW WE INVEST

TAVR developer JenaValve nets $50M from Bain Capital Life Sciences

Share this page